Bruno
Paiva
Profesional Investigador
![Foto de Ana Pilar](/img/nophoto.png)
Ana Pilar
González Rodríguez
Publikationen, an denen er mitarbeitet Ana Pilar González Rodríguez (6)
2024
-
Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance
Journal of Clinical Oncology, Vol. 42, Núm. 27, pp. 3247-3256
-
Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma
Blood, Vol. 143, Núm. 7, pp. 597-603
-
Selinexor, daratumumab, bortezomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma: results of the phase II, non-randomized, multicenter GEM-SELIBORDARA study
Haematologica, Vol. 109, Núm. 7, pp. 2219-2228
2022
-
A Machine Learning Model Based on Tumor and Immune Biomarkers to Predict Undetectable MRD and Survival Outcomes in Multiple Myeloma
Clinical cancer research : an official journal of the American Association for Cancer Research
-
Prognostic Value of Serum Paraprotein Response Kinetics in Patients With Newly Diagnosed Multiple Myeloma
Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, Núm. 9, pp. e844-e852
2019
-
Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma
Blood, Vol. 134, Núm. 16, pp. 1337-1345